JPWO2023234376A1 - - Google Patents

Info

Publication number
JPWO2023234376A1
JPWO2023234376A1 JP2024524929A JP2024524929A JPWO2023234376A1 JP WO2023234376 A1 JPWO2023234376 A1 JP WO2023234376A1 JP 2024524929 A JP2024524929 A JP 2024524929A JP 2024524929 A JP2024524929 A JP 2024524929A JP WO2023234376 A1 JPWO2023234376 A1 JP WO2023234376A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024524929A
Other languages
Japanese (ja)
Other versions
JP7684519B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2023234376A1 publication Critical patent/JPWO2023234376A1/ja
Priority to JP2025082087A priority Critical patent/JP7818130B2/ja
Application granted granted Critical
Publication of JP7684519B2 publication Critical patent/JP7684519B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024524929A 2022-05-31 2023-05-31 ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法 Active JP7684519B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025082087A JP7818130B2 (ja) 2022-05-31 2025-05-15 ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022088995 2022-05-31
JP2022088995 2022-05-31
PCT/JP2023/020372 WO2023234376A1 (ja) 2022-05-31 2023-05-31 ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025082087A Division JP7818130B2 (ja) 2022-05-31 2025-05-15 ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法

Publications (2)

Publication Number Publication Date
JPWO2023234376A1 true JPWO2023234376A1 (https=) 2023-12-07
JP7684519B2 JP7684519B2 (ja) 2025-05-27

Family

ID=89024934

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024524929A Active JP7684519B2 (ja) 2022-05-31 2023-05-31 ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法
JP2025082087A Active JP7818130B2 (ja) 2022-05-31 2025-05-15 ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025082087A Active JP7818130B2 (ja) 2022-05-31 2025-05-15 ヒアルロン酸誘導体、医薬組成物、及び医薬組成物の製造方法

Country Status (7)

Country Link
US (1) US20250339460A1 (https=)
EP (1) EP4534566A4 (https=)
JP (2) JP7684519B2 (https=)
KR (1) KR20240164786A (https=)
CN (1) CN119301160A (https=)
TW (2) TW202515587A (https=)
WO (1) WO2023234376A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202600172A (zh) * 2024-04-11 2026-01-01 日商旭化成股份有限公司 載體組合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020158771A1 (ja) * 2019-01-29 2020-08-06 国立大学法人三重大学 がんワクチン製剤
WO2021157665A1 (ja) * 2020-02-07 2021-08-12 旭化成株式会社 ヒアルロン酸誘導体、医薬組成物及びヒアルロン酸誘導体－薬物結合体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759322B2 (en) * 2008-11-05 2014-06-24 National University Corporation Tokyo Medical And Dental University Hyaluronic acid derivative and pharmaceutical composition thereof
WO2014038641A1 (ja) * 2012-09-05 2014-03-13 中外製薬株式会社 アミノ酸およびステリル基が導入されたヒアルロン酸誘導体
ES3044918T3 (en) 2016-03-25 2025-11-27 The Univ Of Osaka Conjugate vaccine targeting disorder-causing in vivo protein
JP2022088995A (ja) 2020-12-03 2022-06-15 株式会社椿本チエイン ワーク保持装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020158771A1 (ja) * 2019-01-29 2020-08-06 国立大学法人三重大学 がんワクチン製剤
WO2021157665A1 (ja) * 2020-02-07 2021-08-12 旭化成株式会社 ヒアルロン酸誘導体、医薬組成物及びヒアルロン酸誘導体－薬物結合体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"シリカ−疎水化ヒアルロン酸複合ヒドロゲルの合成", 日本化学会春季年会講演予稿集(CD-ROM), JPN6021014834, 2019, ISSN: 0005535768 *
"疎水化ヒアルロン酸−リン酸カルシウムハイブリッド微粒子の合成", 日本化学会春季年会講演予稿集(CD-ROM), JPN6021014836, 2016, ISSN: 0005535769 *

Also Published As

Publication number Publication date
TWI870882B (zh) 2025-01-21
JP2025113317A (ja) 2025-08-01
KR20240164786A (ko) 2024-11-20
JP7684519B2 (ja) 2025-05-27
TW202515587A (zh) 2025-04-16
EP4534566A1 (en) 2025-04-09
EP4534566A4 (en) 2025-09-03
JP7818130B2 (ja) 2026-02-19
CN119301160A (zh) 2025-01-10
US20250339460A1 (en) 2025-11-06
WO2023234376A1 (ja) 2023-12-07
TW202402308A (zh) 2024-01-16

Similar Documents

Publication Publication Date Title
JPWO2023234376A1 (https=)
BR102023014872A2 (https=)
BR102023007252A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
CN307045568S (https=)
BY13144U (https=)
BY13142U (https=)
BY13141U (https=)
BY13140U (https=)
BY13139U (https=)
BY13138U (https=)
BY13137U (https=)
CN307049661S (https=)
CN307049635S (https=)
CN307049310S (https=)
CN307049262S (https=)
CN307048413S (https=)
BY13136U (https=)
CN307047482S (https=)
CN307047006S (https=)
CN307045709S (https=)
BY13156U (https=)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240808

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250401

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250515

R150 Certificate of patent or registration of utility model

Ref document number: 7684519

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150